List of Excipients in API netupitant and palonosetron
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing netupitant and palonosetron
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Helsinn Therapeutics (US) Inc | AKYNZEO | netupitant and palonosetron | 69639-101 | BUTYLATED HYDROXYANISOLE | 2035-09-25 |
| Helsinn Therapeutics (US) Inc | AKYNZEO | netupitant and palonosetron | 69639-101 | CAPRYLIC/CAPRIC MONO/DIGLYCERIDES | 2035-09-25 |
| Helsinn Therapeutics (US) Inc | AKYNZEO | netupitant and palonosetron | 69639-101 | CELLULOSE, MICROCRYSTALLINE | 2035-09-25 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for netupitant and palonosetron
Excipient focus: BUTYLATED HYDROXYANISOLE
netupitant and palonosetron drug variants containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CAPRYLIC/CAPRIC MONO/DIGLYCERIDES
netupitant and palonosetron drug variants containing CAPRYLIC/CAPRIC MONO/DIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing CAPRYLIC/CAPRIC MONO/DIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
netupitant and palonosetron drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
netupitant and palonosetron drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
netupitant and palonosetron drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
netupitant and palonosetron drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
netupitant and palonosetron drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERIN
netupitant and palonosetron drug variants containing GLYCERIN
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing GLYCERIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
netupitant and palonosetron drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYGLYCERYL-3 DIOLEATE
netupitant and palonosetron drug variants containing POLYGLYCERYL-3 DIOLEATE
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing POLYGLYCERYL-3 DIOLEATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE K30
netupitant and palonosetron drug variants containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
netupitant and palonosetron drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STEARYL FUMARATE
netupitant and palonosetron drug variants containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITOL
netupitant and palonosetron drug variants containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SUCROSE LAURATE
netupitant and palonosetron drug variants containing SUCROSE LAURATE
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing SUCROSE LAURATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
netupitant and palonosetron drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
netupitant and palonosetron drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Helsinn Therapeutics (US) Inc | netupitant and palonosetron | 69639-101 |
| >Company | >Ingredient | >NDC |
netupitant and palonosetron drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
